VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISA 2022 | AFFIRM-AL: birtamimab vs placebo in patients with Mayo Stage IV AL amyloidosis

Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, outlines the rationale of AFFIRM-AL (NCT04973137), a Phase III trial evaluating the efficacy and safety of birtamimab plus standard of care (SOC) compared to placebo plus SOC in patients with Mayo Stage IV AL amyloidosis. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

Disclosures

Honoraria: Celgene, Med Learning Group, Research to Practice, Prothena, Apellis Pharmaceuticals, Amgen, AbbVie, Akcea Therapeutics, Sanofi, Telix Pharmaceuticals, Janssen Oncology, Juno/Celgene
Consulting or Advisory Role: Prothena, Bristol Myers Squibb/Sanofi
Travel, Accommodations, Expenses: Prothena, Celgene, Novartis

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter